Personalis, Inc.
PSNL US71535D1063
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Annual Performance 1
2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
-59% | -86% | 4% | 183% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Tachibana Aaron CFO |
6.57 USD |
641 Sold |
4,211 USD |
28/07/2025 | 28/07/2025 |
Chen Richard CMO |
6.57 USD |
452 Sold |
2,970 USD |
28/07/2025 | 28/07/2025 |
Chen Richard CMO |
4.95 USD |
910 Sold |
4,505 USD |
16/05/2025 | 16/05/2025 |
Chen Richard CMO |
4.95 USD |
910 Sold |
4,505 USD |
16/05/2025 | 16/05/2025 |
Moore Stephen Michael VP |
4.95 USD |
1,675 Sold |
8,291 USD |
16/05/2025 | 16/05/2025 |
Moore Stephen Michael VP |
4.95 USD |
1,675 Sold |
8,291 USD |
16/05/2025 | 16/05/2025 |
Tachibana Aaron CFO |
4.95 USD |
1,291 Sold |
6,390 USD |
16/05/2025 | 16/05/2025 |
Tachibana Aaron CFO |
5.79 USD |
708 Sold |
4,099 USD |
28/01/2025 | 28/01/2025 |
Chen Richard CMO |
5.79 USD |
519 Sold |
3,005 USD |
28/01/2025 | 28/01/2025 |
Tachibana Aaron CFO |
3.82 USD |
6,865 Sold |
26,224 USD |
16/12/2024 | 16/12/2024 |